Biocytogen Pharmaceuticals (Beijing) Co Ltd (02315.HK)

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The firm utilizes its self-developed RenMice fully human antibody and T-cell receptor (TCR) mouse platform for large-scale drug discovery and development targeting potential drug targets in the human body. The Company’s main businesses include the sale of innovative animal models, pre-clinical pharmacology and efficacy evaluation services, and antibody development. The firm is also engaged in the provision of gene-editing services. The firm operates its businesses in the domestic market and overseas markets.